SG Americas Securities LLC Reduces Holdings in Edwards Lifesciences Co. (NYSE:EW)

SG Americas Securities LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 22.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 28,998 shares of the medical research company’s stock after selling 8,482 shares during the period. SG Americas Securities LLC’s holdings in Edwards Lifesciences were worth $2,211,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in EW. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $25,000. Compass Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $31,000. Jackson Grant Investment Advisers Inc. acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $38,000. Janiczek Wealth Management LLC grew its position in Edwards Lifesciences by 108.6% during the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in Edwards Lifesciences in the first quarter valued at $49,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE EW opened at $95.15 on Thursday. The business has a 50 day moving average price of $85.48 and a 200 day moving average price of $75.86. The company has a market capitalization of $57.21 billion, a P/E ratio of 41.37, a PEG ratio of 4.62 and a beta of 1.05. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $95.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the business posted $0.64 earnings per share. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Oppenheimer increased their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Truist Financial lifted their target price on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Citigroup cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Monday, December 11th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. Finally, Mizuho boosted their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $88.50.

Insider Activity

In related news, CFO Scott B. Ullem sold 14,510 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $76.55, for a total transaction of $1,110,740.50. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,473,434.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at $327,388.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 14,510 shares of the business’s stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $76.55, for a total transaction of $1,110,740.50. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,473,434.40. The disclosure for this sale can be found here. Insiders have sold 196,859 shares of company stock worth $16,445,296 over the last ninety days. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.